Sugi Predict

Sugi Predict / Compounds / SCHEMBL21998273

SCHEMBL21998273

SCHEMBL21998273

COC(=O)c1ccnc2ccc(OC)nc12

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ PSMD14 O00487 1/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ KDM4E B2RXH2 5/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ GAA P10253 3/20 0.42
▸ ATM Q13315 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ NNMT P40261 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ KCNH2 Q12809 4/20 0.39
▸ MAP2K1 Q02750 1/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29948108 1.00 L3MBTL1 (0.45) L3MBTL1PSMD14ALOX15HTTKDM4E
SCHEMBL5309028 0.88 LMNA (0.43) KDM4EKMT2ALMNAPOLBTDP1
SCHEMBL5826544 0.85 NNMT (0.54) KDM4ELMNAPOLBTDP1NNMT
Hydrochloric Acid SCHEMBL6756852 0.84 NNMT (0.53) KDM4ELMNAPOLBTDP1NNMT
SCHEMBL29918750 0.83 PSMD14 (0.43) L3MBTL1PSMD14ALOX15HTTKDM4E
SCHEMBL21997997 0.83 PSMD14 (0.43) L3MBTL1PSMD14ALOX15HTTKDM4E
SCHEMBL3543451 0.83 LMNA (0.38) KDM4ELMNAPOLBTDP1NNMT
SCHEMBL21997740 0.82 ATR (0.46) L3MBTL1PSMD14ALOX15HTTKDM4E
SCHEMBL29918790 0.82 ATR (0.46) L3MBTL1PSMD14ALOX15HTTKDM4E
SCHEMBL2918923 0.81 HPGDS (0.40) KDM4ELMNAPOLBTDP1NNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed
EP-4076536-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-10-26 — — EP disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2021127278-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PSMD14 249/4885ALOX15 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.